Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TNF | P01375 | 1/20 | 0.34 |
| ▸ | RIPK1 | Q13546 | 1/20 | 0.34 |
| ▸ | AKR1C3 | P42330 | 1/20 | 0.32 |
| ▸ | AKR1C2 | P52895 | 1/20 | 0.32 |
| ▸ | HTR2A | P28223 | 3/20 | 0.31 |
| ▸ | HTR2C | P28335 | 3/20 | 0.31 |
| ▸ | HTR2B | P41595 | 3/20 | 0.31 |
| ▸ | MEN1 | O00255 | 1/20 | 0.31 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.31 |
| ▸ | HTT | P42858 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL23138933 | 0.86 | NOTUM (0.33) | AKR1C3AKR1C2HTT | |
| SCHEMBL12286582 | 0.86 | NOTUM (0.38) | TNFRIPK1HTT | |
| SCHEMBL78563 | 0.84 | TNF (0.31) | TNFRIPK1 | |
| SCHEMBL803641 | 0.84 | CYP3A4 (0.31) | — | |
| SCHEMBL24945815 | 0.82 | DAO (0.35) | TNFRIPK1MEN1KMT2AHTT | |
| SCHEMBL22570314 | 0.79 | HTR2A (0.42) | HTR2AHTR2CHTR2BMEN1KMT2A | |
| SCHEMBL24252047 | 0.78 | HTR2A (0.31) | TNFRIPK1HTR2AHTR2CHTR2B | |
| SCHEMBL8220621 | 0.77 | POLB (0.31) | — | |
| SCHEMBL10256478 | 0.76 | HTT (0.32) | HTR2AHTR2BHTT | |
| SCHEMBL19813279 | 0.76 | TSHR (0.40) | AKR1C3AKR1C2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230373985-A1 | KINASE MODULATORS AND METHODS OF USE THEREOF | ORIGENIS GMBH (DE) | 2023-11-23 | — | — | US | disclosed |
| US-20230373985-A1 | KINASE MODULATORS AND METHODS OF USE THEREOF | ORIGENIS GMBH (DE) | 2023-11-23 | — | — | US | disclosed |
| US-20220048915-A1 | Nitrogen-containing Heterocyclic Compound and Composition Thereof, Preparation Method Therefor, and Application Thereof | SHANGHAI PHARMACEUTICALS HOLDING CO., LTD. (CN) | 2022-02-17 | — | — | US | disclosed |
| US-20210087147-A1 | SELECTIVE INHIBITORS OF NLRP3 INFLAMMASOME | NodThera Limited (GB) | 2021-03-25 | — | — | US | disclosed |
| US-20120135975-A1 | Substituted Esters as Cannabinoid-1 Receptor Modulators | MERCK & CO., INC. (US) | 2012-05-31 | — | — | US | disclosed |
| US-8129538-B1 | Renin inhibitors | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2012-03-06 | — | — | US | disclosed |
| US-20080312435-A1 | Imine Compound | TAISHO PHARMACEUTICAL CO., LTD. (JP) | 2008-12-18 | — | — | US | disclosed |
| US-20080312435-A1 | Imine Compound | TAISHO PHARMACEUTICAL CO., LTD. (JP) | 2008-12-18 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080312435-A1 | Imine Compound | CNR1, CNR2, HRH4 | TNF 1859/4885RIPK1 834/4885AKR1C3 647/4885 |
| US-20230373985-A1 | KINASE MODULATORS AND METHODS OF USE THEREOF | TYK2, MAPKAPK2, MAP3K20 | TNF 839/4885RIPK1 32/4885AKR1C3 4423/4885 |
| US-20220048915-A1 | Nitrogen-containing Heterocyclic Compound and Composition Thereof, Preparation Method Therefor, and Application Thereof | MAPK11, WEE1, NOS1 | TNF 1461/4885RIPK1 1677/4885AKR1C3 1539/4885 |
| US-20120135975-A1 | Substituted Esters as Cannabinoid-1 Receptor Modulators | CNR1, CNR2, FAAH | TNF 1324/4885RIPK1 1973/4885AKR1C3 2556/4885 |
| US-20210087147-A1 | SELECTIVE INHIBITORS OF NLRP3 INFLAMMASOME | NLRP3, NOD1, NLRP1 | TNF 62/4885RIPK1 80/4885AKR1C3 880/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.